These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35077998)

  • 1. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.
    Huang C; He Y; Sun J; Yuan Q; Li S; Hou H; Su K; Ke C; Du Z; Yuan Z
    Acta Histochem; 2022 Feb; 124(2):151856. PubMed ID: 35077998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.
    Su K; Yuan Q; Hou H; Ke C; Huang C; Li S; Sun J; Yuan X; Lin Y; Chen Y; Xin H; Liang X; Du Z; Yuan Z
    J Mol Med (Berl); 2022 Apr; 100(4):629-643. PubMed ID: 35247069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).
    Hou H; Su K; Huang C; Yuan Q; Li S; Sun J; Lin Y; Du Z; Ke C; Yuan Z
    Adv Healthc Mater; 2021 Jun; 10(11):e2100030. PubMed ID: 33963815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.
    Gneo L; Ruggeri P; Cappabianca L; Farina AR; Di Ianni N; Mackay AR
    Oncotarget; 2016 Dec; 7(49):80820-80841. PubMed ID: 27821809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines.
    Polanski R; Vincent J; Polanska UM; Petreus T; Tang EK
    Cell Death Dis; 2015 Oct; 6(10):e1893. PubMed ID: 26426685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells.
    Wang MJ; Liu S; Liu Y; Zheng D
    Neurosci Res; 2007 Sep; 59(1):40-6. PubMed ID: 17707539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP.
    Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N
    Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of gamma-interferon with TRAIL and cisplatin or etoposide induces apoptosis in human neuroblastoma cell line SH-SY5Y.
    Tong HX; Lu CW; Zhang JH; Ma L; Zhang JH
    Chin Med Sci J; 2007 Mar; 22(1):38-43. PubMed ID: 17441316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
    Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
    Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
    Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
    Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.
    Liu PC; Lu G; Deng Y; Wang CD; Su XW; Zhou JY; Chan TM; Hu X; Poon WS
    PLoS One; 2017; 12(1):e0171157. PubMed ID: 28135339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
    Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
    Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NGF sensitizes TrkA SH-SY5Y neuroblastoma cells to TRAIL-induced apoptosis.
    Ruggeri P; Cappabianca L; Farina AR; Gneo L; Mackay AR
    Cell Death Discov; 2016; 2():16004. PubMed ID: 27551499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines.
    Engelsgjerd S; Kunnimalaiyaan S; Kandil E; Gamblin TC; Kunnimalaiyaan M
    PLoS One; 2019; 14(3):e0213776. PubMed ID: 30870485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
    Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
    J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
    Raguénez G; Mühlethaler-Mottet A; Meier R; Duros C; Bénard J; Gross N
    BMC Cancer; 2009 Mar; 9():97. PubMed ID: 19331667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3‑Bromopyruvate sensitizes human breast cancer cells to TRAIL‑induced apoptosis via the phosphorylated AMPK‑mediated upregulation of DR5.
    Chen Y; Wei L; Zhang X; Liu X; Chen Y; Zhang S; Zhou L; Li Q; Pan Q; Zhao S; Liu H
    Oncol Rep; 2018 Nov; 40(5):2435-2444. PubMed ID: 30132536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.